ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 41
УЖМБС 2017, 2(3): 107–114
Clinical Medicine

Association of CYP11b2 Gene Polymorphism of Aldosteron-Synthase with the Risk of Myocardial Infarction with ST-Segment Elevation

Petyunina O. V.

The purpose of the study is to determine the link between CYP11B2 -344ТС gene polymorphism and risk factors, course of myocardial infarction with ST-segment elevation (STEMI) with considering of genetic inheritance models. Materials and methods. 85 patients with STEMI were examined, 68 (80%) men and 17 (20%) women, at the average age (58,94±10,16) years old. Allele polymorphism -Т344С of CYP11B2 gene was determined by polymerase chain reaction in real time. Statistics was obtained thanks to software package Statistica 8.0 (Stat SoftInc, USA), Microsoft Office Exсel 2003. For a deeper understanding of association of CYP11B2-gene polymorphism, codominant, dominant and recessive models of inheritance were used. Results and discussion. Due to odds ratio the relative risk of occurrence of STEMI in researched patients with TT-genotype rises with the presence of arterial hypertension (AH) OR=8,89; 95% CI [1,41-36,57], Р1-3=0,02 (codominant model of inheritance). In the group of patients with TT-genotype compared with ТС+СС anxiety-depressive conditions met more often (Р=0,02), tendency to more often AH was too (Р=0,06) (dominant inheritance model). Due to odds ratio, probability of occurrence of STEMI in researched patients with ТС+ТТ-genotype becomes higher in the presence of AH, OR=3,27; 95% CI [1,05-9,86], Р=0,037 (recessive inheritance model). Conclusions. ТС+ТТ-genotype compared with СС represents 3,27-fold higher relative risk of occurrence of STEMI in the presence of AH (Р=0,037). Arterial hypertension leads to 8,89-fold more often relative risk of STEMI in patients with ТТ-genotype compared with СС (Р=0,02). Anxiety-depressive conditions in patients with STEMI occur more often in ТТ-genotype compared with СС, ТС+СС polymorphism, ТС+ТТ compared -344СС.

Keywords: acute myocardial infarction with ST-segment elevation, -T344С-polymorphism of CYP11B2 gene, arterial hypertension, anxiety-depressive conditions

Full text: PDF (Ukr) 216K

  1. Brovin DL, Bazhenova EA, Popov RE, i soavt. Raspredelenie genotipov I vstrecharmost allelei gena aldosterone-syntasy u bolnych abdominalnym ozhireniem. Ucheniie zapiski SPb GMU im acad IP Pavlova. 2015; 22 (2): 20-3. [Russian].
  2. Dolzhenko MM, Lobach LE, Potashev SV. Vplyv polimorfismu gena aldosteronsyntasy (CYP11B2) na sertsevo-sudynnu systemu. Ukrainski cardiologichny zhurnal. 2015; 5: 104-9. [Ukrainian].
  3. Lobach LE, Dosenko VE, Dolzhenko MM. Vplyv polimorfismu gena aldosteronsyntasy (CYP11B2) na rysyk rosvytku infarctu miocarda. Ukrainski cardiologichny zhurnal. 2017; 7: 26-9. [Ukrainian].
  4. Tihonova SA, Piskovatska VP. Analis clinichnych, genetychnych i gendernych determinant neefectyvnogo likuvannia u patsientiv z arterialnoiu hypertensieiu. Arterialna hypertensiia. 2016; 3 (47). Available from: [Ukrainian].
  5. Zelіnskaia EM, Koh NV, Kireeva VV, i soavt. Associaciia gena CYP11B2 s riskom razvitiia gipertonicheskoi bolezni i aterotromboticheskih oslozhneniy. Cardiovascularnaia terapiia i profilactica. 2016; 15 (3): 63-8. [Russian].
  6. Bagos PG. Genetic model selection in genome-wide association studies: robust methods and the use of metha-analysis. Stat Appl Genet Mol Biol. 2013; 12 (3): 285-308.
  7. Gomes-Sanchez E, Gomes-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Phisiol. 2014; 4 (3): 965-94.
  8. Hautanen A, Toivanen P, Mänttäri M, Tenkanen L, Kupari M, Manninen V, Kayes KM, Rosenfeld S, White PC. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation. 1999; 100: 2213-8.
  9. Hengstenberg C, Holmer SR, Mayer B, et al. Evaluation of the aldosterone synthase (CYP112B) gene polymorphism in patients with myocardial infarction. Hypertension. 2000; 35: 704-9.
  10. Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results increased anxiety-like behavior. Horm Behav. 2008; 54 (1): 90-7.
  11. Hlubocka Z, Jachymova M, Heller S, et al. Association of the -344T/C aldosterone synthase gene variant with essential hypertension. Physiol Res. 2009; 58: 785-92.
  12. Kubzanski LD, Adler GK. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev. 2010; 34 (1): 80-6.
  13. Murck H, Held K, Ziegenbein M, Künzel H, Koch K, Steiger A. The rennin-angiotensin-aldosteron system in patients with depression compared with controls – a sleep endocrine study. BMC Psychiatry. 2003; 3: 15.
  14. Normaznah Y, Azizah MR, Kuak SH, Rosli MA. CYP11B2 gene polymorphism among coronary heart disease patients and blood donors in Malaysia. Malays J Pathol. 2015; 37 (1): 45-7.
  15. Rajan S, Ramu P. Association of aldosterone synthase (CYP112B – C-344T) gene polymorphism and susceptibility to essential hypertension in a south Indian Tamil population. Indian J Med Res. 2010; 132: 379-85.
  16. Sookoian S, Gianotti TF, González CD, Pirola CJ. Association of the C-344t aldosterone synthase gеnе variant with essential hypertension: a meta-analysis. J Hypertens. 2007; 25 (1): 5-13.
  17. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J. 2007; 54 (3): 359-70.
  18. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-conrol study. Lancet. 2004; 364 (9438): 937-52.
  19. Xu Ji, Hua Qi, Dong-Bao Li, Rong-Kun Liu, Yang Zheng, Hai-Ling Chen, Jin-Cheng Guo. Associations between human aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension. Int J Clin Exp Med. 2015; 8 (1): 1173-7.
  20. Zennaro MC, Rickard AJ, Boulkroun S, et al. Genetics of mineralocorticoid excess: an update for clinicians. European Journal of Endocrinology. 2013: 169: 15-25.